Diligence memo · auto-generated · as of July 2, 2026
ImmunityBio, Inc.
ImmunityBio, Inc. has raised $640M over 8 rounds; too few niche peers to rank its valuation yet.
Businessfiled
ImmunityBio, Inc. operates in Biotechnology, based in SAN DIEGO. We're dedicated to defeating cancer with therapies that target disease, not immune systems. Find our investigational immunotherapy and cell therapy products.
Sub-sector tags: biotech, healthtech.
Capital & rounds (filed)filed
ImmunityBio, Inc. has raised $640M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Growth/Late (a round over $400M).
Largest single filing: $470M on 2023-09-11.
Most recent recorded round closed around 2023-09-11.
Valuation (modeled)modeled
Provath models ImmunityBio, Inc. at approximately $7.8B (range $2.9B–$10.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Historic cadence: a new round about every 21 months.
Last raise 2.8 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 44.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 100% of Biotechnology peers (4293 compared).
Modeled value ranks above 100% of those peers.
Closest niche peers: Denali Therapeutics Inc., Avidity Biosciences, Inc., Inhibrx, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.